Omnicell (OMCL) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
17 Jan, 2026Executive summary
Q3 2024 revenues were $282 million, down 5% year-over-year, with product revenues declining and service revenues increasing, reflecting a challenging environment and timing of the XT Series replacement cycle.
GAAP net income for Q3 2024 was $9 million ($0.19 per diluted share), up from $6 million ($0.12 per diluted share) in Q3 2023; non-GAAP net income was $26 million ($0.56 per diluted share), down from $28 million ($0.62 per diluted share) a year ago.
The company is focused on expanding recurring and predictable revenues, outcome-centric innovation, and operational excellence, with Advanced Services as a key growth driver.
Leadership expanded with the appointment of Nnamdi Njoku as Chief Operating Officer to drive operational change and efficiency.
Omnicell maintains a strong balance sheet, supporting investments in new products and services for sustainable growth.
Financial highlights
Q3 2024 total revenue was $282 million, up $6 million sequentially, but down $16 million year-over-year; product revenue was $158 million, down $30 million year-over-year, and service revenue was $124 million, up $14 million year-over-year.
Non-GAAP gross margin was 44.5%, down 120 basis points year-over-year; GAAP gross margin was 43.3%.
Non-GAAP EBITDA for Q3 2024 was $39 million, down from $41 million in Q3 2023.
Cash and cash equivalents at quarter-end were $571 million, up from $557 million in Q2; total debt was $572 million.
Non-GAAP free cash flow for Q3 2024 was $9 million, compared to $43 million in Q3 2023.
Outlook and guidance
Full-year 2024 total revenue guidance is $1.100–$1.110 billion, with non-GAAP EBITDA of $129–$134 million and non-GAAP EPS of $1.65–$1.72.
Q4 2024 revenue expected at $295–$305 million; product revenue $177–$182 million; service revenue $118–$123 million.
Q4 non-GAAP EBITDA expected at $40–$45 million; non-GAAP EPS $0.55–$0.62.
Bookings for 2024 expected between $800 million and $875 million.
Advanced Services revenue is expected to reach $239–$242 million in 2024, targeted to comprise 22% of total revenue.
Latest events from Omnicell
- Q4 and FY 2025 revenues and ARR rose, with Titan XT and OmniSphere driving growth and strong 2026 outlook.OMCL
Q4 20255 Feb 2026 - Q2 revenue beat guidance; recurring and Advanced Services growth drove raised 2024 outlook.OMCL
Q2 20242 Feb 2026 - Accelerated innovation and advanced services drive growth, margin expansion, and strategic partnerships.OMCL
2024 Wells Fargo Healthcare Conference22 Jan 2026 - XT Amplify and advanced services fuel growth, with specialty pharmacy driving revenue momentum.OMCL
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - AI-powered automation and advanced services are set to drive growth and recurring revenue in 2025.OMCL
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q4 2024 saw 19% revenue growth and strong 2025 guidance driven by innovation and backlog.OMCL
Q4 20246 Jan 2026 - Recurring revenue and SaaS growth drive innovation and financial strength in 2025.OMCL
Investor Presentation15 Dec 2025 - Titan XT launches with cloud, AI, and security upgrades, targeting a $2.5B market.OMCL
Investor Update11 Dec 2025 - Enterprise-focused innovation and leadership reset position for growth and margin expansion in 2026.OMCL
Piper Sandler 37th Annual Healthcare Conference3 Dec 2025